Significant associations of certain HLA alleles or haplotypes with different phenotypical features in a cohort of 282 individuals with psoriatic arthritis
| HLA allele or haplotype previously identified with psoriatic arthritis susceptibility | Phenotypic feature | Frequency† (%) of trait in those with HLA | Frequency (%) of HLA in those with trait | Frequency (%) of HLA in those without trait | OR | p Value‡ (two sided) |
|---|---|---|---|---|---|---|
| B*27:05:02 | Symmetrical sacroiliitis | 24.4 | 61.1 | 12.9 | 10.6 (3.8 to 29) | <0.0001 |
| C*01:02:01 | 21.9 | 36.8 | 9.5 | 5.6 (2.0 to 15.4) | <0.0001 | |
| C*02:02:02 | 22.7 | 26.3 | 6.4 | 5.1 (1.7 to 16) | 0.002 | |
| B*27:05:02-C*01:02:01 | 24 | 31.6 | 7.2 | 6.0 (2.0 to 17) | <0.0001 | |
| B*27:05:02-C*02:02:02 | 26.3 | 26.3 | 5.3 | 6.3 (2.0 to 20) | <0.0001 | |
| B*08:01:01 | 2.9 | 16.7 | 38.3 | 0.32 (0.09 to 1.14) | 0.07 | |
| C*07:01:01 | 2.6 | 15.8 | 42.4 | 0.25 (0.07 to 0.89) | 0.022 | |
| B*08:01:01-C*07:01:01 | 2.9 | 15.8 | 37.5 | 0.31 (0.08 to 1.1) | 0.057 | |
| B*08:01:01 | Aymmetrical sacroiliitis | 30.8 | 62.7 | 31.2 | 3.7 (1.9 to 6.9) | <0.0001 |
| C*07:01:01 | 27 | 60.8 | 36.2 | 2.7 (1.4 to 5.0) | <0.0001 | |
| B*08:01:01-C*07:01:01 | 29.4 | 58.4 | 31 | 3.1 (1.7 to 5.9) | <0.0001 | |
| C*06:02:01 | 10.8 | 17.6 | 31.9 | 0.45 (0.21 to 0.98) | 0.043 | |
| B*57:01:01 | 7.4 | 7.8 | 21.6 | 0.31 (0.10 to 0.90) | 0.023 | |
| B*57:01:01-C*06:02:01 | 7.4 | 7.8 | 21.6 | 0.31 (0.10 to 0.90) | 0.023 | |
| C*05:01:01 | 28.3 | 25.5 | 14.2 | 2.1 (1.0 to 4.3) | 0.048 | |
| B*27:05:02 | Enthesitis | 60 | 28.1 | 9.7 | 3.7 (1.9 to 7.1) | <0.0001 |
| C*01:02:01 | 65.6 | 21.6 | 5.9 | 4.4 (2.0 to 9.6) | <0.0001 | |
| B*27:05:02-C*01:02:01 | 68 | 17.5 | 4.3 | 4.7 (2.0 to 11) | <0.0001 | |
| B*27:05:02 | Dactylitis | 71.1 | 21.3 | 9.8 | 2.5 (1.2 to 5.0) | 0.009 |
| C*02:02:02 | 72.7 | 10.7 | 4.5 | 2.5 (1.0 to 6.7) | 0.05 | |
| B*27:05:02-C*01:02:01 | 72 | 12.0 | 5.3 | 2.5 (1.0 to 6.1) | 0.05 | |
| B*08:01:01 | 61.5 | 42.7 | 30.3 | 1.7 (1.1 to 2.8) | 0.03 | |
| C*07:01:01 | 63.5 | 48.7 | 31.6 | 2 (1.3 to 3.3) | 0.003 | |
| B*08:01:01-C*07:01:01 | 61.8 | 42.0 | 29.3 | 1.8 (1.1 to 2.9) | 0.03 | |
| B*44:02:01 | 32.6 | 9.3 | 22.0 | 0.37 (0.2 to 0.7) | 0.003 | |
| B*44:02:01-C*05:01:01 | 35.1 | 8.7 | 18.0 | 0.43 (0.2 to 0.89) | 0.02 | |
| B*44:03:01 | 31 | 6.0 | 15.2 | 0.36 (0.2 to 0.8) | 0.012 | |
| C*16:01:01 | 31.6 | 4.0 | 9.8 | 0.4 (0.1 to 1.0) | 0.05 | |
| B*44:03:01-C*16:01:01 | 27.8 | 3.3 | 9.8 | 0.3 (0.1 to 0.9) | 0.03 | |
| B*08:01:01 | Joint | 38.5 | 48.8 | 32.0 | 2 (1.2 to 3.4) | 0.008 |
| C*07:01:01 | Fusion | 38.3 | 53 | 35.5 | 2 (1.2 to 3.4) | 0.006 |
| B*08:01:01-C*07:01:01 | 39.2 | 48.2 | 31.0 | 2 (1.2 to 3.4) | 0.006 | |
| B*37:01:01 | 57.9 | 13.4 | 4.0 | 3.7 (1.4 to 9.6) | 0.004 | |
| B*37:01:01-C*06:02:01 | 57.9 | 13.3 | 4.0 | 3.7 (1.4 to 9.5) | 0.005 | |
| B*44:02:01 | 9.3 | 4.9 | 19.5 | 0.21 (0.07 to 0.6) | 0.002 | |
| C*05:01:01 | 13 | 7.2 | 20.0 | 0.31 (0.12 to 0.76) | 0.008 | |
| B*44:02:01-C*05:01:01 | 10.8 | 4.8 | 16.5 | 0.26 (0.09 to 0.75) | 0.004 | |
| B*44:03:01 | 10.3 | 3.7 | 13.0 | 0.25 (0.08 to 0.97) | 0.019 | |
| C*16:01:01 | 10.5 | 2.4 | 8.5 | 0.3 (0.1 to 1.2) | 0.06 | |
| B*44:03:01-C*16:01:01 | 5.6 | 1.2 | 8.5 | 0.13 (0.01 to 1.00) | 0.02 | |
| B*08:01:01 | Joint deformity | 76 | 43.4 | 25.0 | 2.3 (1.3 to 4) | 0.002 |
| C*07:01:01 | 73.9 | 46.4 | 30.0 | 2 (1.2 to 3.3) | 0.007 | |
| B*08:01:01-C*07:01:01 | 75.5 | 42.1 | 25.0 | 2 (1.2 to 3.7) | 0.004 | |
| B*44:03:01 | 44.8 | 7.1 | 16.0 | 0.41 (0.2 to 0.88) | 0.019 | |
| C*16:01:01 | 36.8 | 3.8 | 12.0 | 0.29 (0.1 to 0.76) | 0.009 | |
| B*44:03:01-C*16:01:01 | 33.3 | 3.3 | 12.0 | 0.24 (0.09 to 0.68) | 0.004 | |
| C*02:02:02 | Osteolysis | 31.8 | 17.1 | 6.3 | 3.1 (1.2 to 8.1) | 0.02 |
| C*01:02:01 | Erosion | 64.5 | 16.3 | 7.0 | 2.6 (1.2 to 5.6) | 0.01 |
| B*27:05:02-C*01:02:01 | 64 | 13.0 | 5.7 | 2.5 (1.1 to 5.8) | 0.03 | |
| B*44:02:01 | 30.2 | 10.7 | 19.0 | 0.51 (0.25 to 1.0) | 0.055 | |
| B*44:02:01-C*05:01:01 | 29.7 | 8.9 | 16.5 | 0.5 (0.2 to 1.1) | 0.065 |
†Genotypic frequency.
‡Pearson χ2 two-sided asymptomatic significance.
HLA, human leukocyte antigen.